These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 33333396)

  • 1. Development of Mcl-1 inhibitors for cancer therapy.
    Negi A; Murphy PV
    Eur J Med Chem; 2021 Jan; 210():113038. PubMed ID: 33333396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
    Wan Y; Dai N; Tang Z; Fang H
    Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MCL-1 inhibitors - where are we now (2019)?
    Fletcher S
    Expert Opin Ther Pat; 2019 Nov; 29(11):909-919. PubMed ID: 31566022
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present).
    Fan Y; Hou X; Fang H
    Recent Pat Anticancer Drug Discov; 2020; 15(4):306-320. PubMed ID: 32938354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
    Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
    J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
    Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
    J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy.
    Senichkin VV; Streletskaia AY; Zhivotovsky B; Kopeina GS
    Trends Cell Biol; 2019 Jul; 29(7):549-562. PubMed ID: 31030977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
    Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
    Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy.
    Zhu PJ; Yu ZZ; You QD; Jiang ZY
    Drug Discov Today; 2020 Oct; 25(10):1873-1882. PubMed ID: 32771436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
    Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
    Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
    Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
    Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and preliminary biological studies of pyrrolidine derivatives as Mcl-1 inhibitors.
    Wan Y; Wang J; Sun F; Chen M; Hou X; Fang H
    Bioorg Med Chem; 2015 Dec; 23(24):7685-93. PubMed ID: 26620718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule Mcl-1 inhibitors for the treatment of cancer.
    Belmar J; Fesik SW
    Pharmacol Ther; 2015 Jan; 145():76-84. PubMed ID: 25172548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the development of Mcl-1 inhibitors for cancer therapy.
    Hird AW; Tron AE
    Pharmacol Ther; 2019 Jun; 198():59-67. PubMed ID: 30790641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
    Beekman AM; O'Connell MA; Howell LA
    ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
    Wan Y; Liu T; Li X; Chen C; Fang H
    Bioorg Med Chem; 2017 Jan; 25(1):138-152. PubMed ID: 27810438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mcl-1 inhibitors: a patent review.
    Chen L; Fletcher S
    Expert Opin Ther Pat; 2017 Feb; 27(2):163-178. PubMed ID: 27744724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Optimization of 3-Phenyl-
    Li Y; Fan W; Gong Q; Tian J; Zhou M; Li Q; Uwituze LB; Zhang Z; Hong R; Wang R
    J Med Chem; 2021 Jul; 64(14):10260-10285. PubMed ID: 34228434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.
    Liu L; Liu R; Yang X; Hou X; Fang H
    Eur J Med Chem; 2020 Apr; 191():112142. PubMed ID: 32088497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
    Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
    Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.